Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials • Medical Devices & Mechanical Engineering
11 pending office actions • 9 clients • 11 examiners • 8 art units • 0 of 11 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days
Synergy IP Group AG has managed 137 career applications, primarily in Biotechnology & Pharmaceuticals. The firm has a resolved allowance rate pct of 63.89. This figure reflects the firm's success in obtaining allowances for its resolved applications across its 137 career applications.
The firm averages 3.57 office actions per allowance, which describes the typical level of examiner interaction for each grant. Currently, there are 8 pending office actions. This workload is managed within the context of the firm's established practice in the Biotechnology & Pharmaceuticals technology area.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (18%) |
| §103 only | 3 (27%) |
| Double-patenting + other | 2 (18%) |
| Multi-statute (no §101) | 4 (36%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ESPINOSA, CLAUDIA EDILMA | 1 | 50.9% | +57.7% |
| SHI, GENBIN | 1 | — | — |
| JACKSON III, WALTER | 1 | 100.0% | +0.0% |
| HOLTZCLAW, MICHAEL T. | 1 | 77.6% | +16.0% |
| MOORE, MARGARET G | 1 | 68.0% | +15.2% |
| FAN, LYNN Y | 1 | 47.3% | +49.5% |
| SORKIN, DAVID L | 1 | 67.4% | +12.8% |
| ATKINSON, JOSHUA ALEXANDER | 1 | 52.4% | +26.7% |
| ABBAS, ABDULRAHMAN MUSTAFA | 1 | 52.4% | +34.8% |
| PAZ ESTEVEZ, GUILLERMO G | 1 | 21.4% | +5.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17595393 | METHOD FOR PRODUCING NANOPARTICLES | HOLT, ANDRIAE M | 5d |
| 18725818 | Ovomucoid for use in a method of managing blood coagulation | ESPINOSA, CLAUDIA EDILMA | — |
| 18716156 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | SHI, GENBIN | — |
| 18423327 | 3D ARTIFICIAL SKIN MODEL AND METHOD FOR PRODUCING THE SAME | JACKSON III, WALTER | — |
| 18566112 | METHOD AND APPARATUS FOR SELECTIVE APPLICATION OF STIMULUS LIGHT | HOLTZCLAW, MICHAEL T. | — |
| 18549476 | TREATMENT OF EYE DISEASES WITH FRUCTOSYL-AMINO ACID OXIDASE | FAN, LYNN Y | — |
| 17776226 | ADAPTER FOR A DRUG MIXING AND INJECTION SYSTEM | PAZ ESTEVEZ, GUILLERMO G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17999851 | METHOD FOR PRODUCING A LIPOSOME DISPERSION | ATKINSON, JOSHUA ALEXANDER | 28d |
| 18725818 | Ovomucoid for use in a method of managing blood coagulation | ESPINOSA, CLAUDIA EDILMA | — |
| 18566112 | METHOD AND APPARATUS FOR SELECTIVE APPLICATION OF STIMULUS LIGHT | HOLTZCLAW, MICHAEL T. | — |
| 18557303 | COMPOSITIONS AND METHODS OF REDUCING AGGREGATION OF MOLECULES | MOORE, MARGARET G | — |
| 18549476 | TREATMENT OF EYE DISEASES WITH FRUCTOSYL-AMINO ACID OXIDASE | FAN, LYNN Y | — |
| 18042460 | JET IMPINGEMENT REACTOR | SORKIN, DAVID L | — |
| 17778007 | PROCESS FOR THE PREPARATION OF DISPERSIONS COMPRISING INHALABLE IMMUNOSUPPRESSIVE ACTIVE INGREDIENTS | ABBAS, ABDULRAHMAN MUSTAFA | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Leon-Nanodrugs | 3 |
| Solution Shop AG | 1 |
| Nanjing Zenshine Pharmaceuticals Co., Ltd. | 1 |
| KAIST | 1 |
| Dopavision GmbH | 1 |
| Ludwig-Maximilians-Universitaet Muenchen | 1 |
| UNIVERSITEIT GENT | 1 |
| Zambon | 1 |
| Activoris Medizintechnik GmbH | 1 |
| Art Unit | Apps |
|---|---|
| 1612 | 2 |
| 1638 | 1 |
| 3796 | 1 |
| 1765 | 1 |
| 1759 | 1 |
| 1774 | 1 |
| 3783 | 1 |
| 1614 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18725818 | Ovomucoid for use in a method of managing blood coagulation | Solution Shop AG | ESPINOSA, CLAUDIA EDILMA | §101§102§112Other | Non-Final OA | — | Pending | Jul 01, 2024 | |
| 18716156 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | Nanjing Zenshine Pharmaceuticals Co., Ltd. | SHI, GENBIN | §103§112 | Non-Final OA | — | Pending | Jun 04, 2024 | |
| 18423327 | 3D ARTIFICIAL SKIN MODEL AND METHOD FOR PRODUCING THE SAME | Korea Advanced Institute Of Science And Technology | JACKSON III, WALTER | 1638 | §102§103 | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18566112 | METHOD AND APPARATUS FOR SELECTIVE APPLICATION OF STIMULUS LIGHT | Dopavision GmbH | HOLTZCLAW, MICHAEL T. | 3796 | §102§103§112 | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18557303 | COMPOSITIONS AND METHODS OF REDUCING AGGREGATION OF MOLECULES | Ludwig-Maximilians-Universitaet Muenchen | MOORE, MARGARET G | 1765 | §103 | Final Rejection | — | Pending | Oct 26, 2023 |
| 18549476 | TREATMENT OF EYE DISEASES WITH FRUCTOSYL-AMINO ACID OXIDASE | UNIVERSITEIT GENT | FAN, LYNN Y | 1759 | §101§102§103 | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18042460 | JET IMPINGEMENT REACTOR | Leon-Nanodrugs GmbH | SORKIN, DAVID L | 1774 | §103 | Non-Final OA | — | Pending | Feb 22, 2023 |
| 17999851 | METHOD FOR PRODUCING A LIPOSOME DISPERSION | Leon-Nanodrugs GmbH | ATKINSON, JOSHUA ALEXANDER | 1612 | §103DP | Final Rejection | 28d | Pending | Nov 24, 2022 |
| 17778007 | PROCESS FOR THE PREPARATION OF DISPERSIONS COMPRISING INHALABLE IMMUNOSUPPRESSIVE ACTIVE INGREDIENTS | ZAMBON S.P.A. | ABBAS, ABDULRAHMAN MUSTAFA | 1612 | §103DP | Non-Final OA | — | Pending | May 19, 2022 |
| 17776226 | ADAPTER FOR A DRUG MIXING AND INJECTION SYSTEM | Activoris Medizintechnik GmbH | PAZ ESTEVEZ, GUILLERMO G | 3783 | §103 | Final Rejection | — | Pending | May 12, 2022 |
| 17595393 | METHOD FOR PRODUCING NANOPARTICLES | Leon-Nanodrugs GmbH | HOLT, ANDRIAE M | 1614 | §103§112 | Final Rejection | 5d | Pending | Nov 16, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial